Voronoi Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 146

Employees

  • Stock Symbol
  • 310210

Stock Symbol

  • Share Price
  • $83.18
  • (As of Friday Closing)

Voronoi General Information

Description

Voronoi Inc is a biotech company that develops novel kinase inhibitors and targets protein degraders. It is principally focused on developing targeted therapies for anticancer drugs such as lung and breast cancer. Its pipeline products are: VRN11, VRN16, VRN10, VRN19, VRN07, VRN04, VRN06, and others.

Contact Information

Website
www.voronoi.io
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 18th Floor, IT Centre South
  • Sondogwahak-ro, Yeonsu-gu
  • Incheon, 21999
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 18th Floor, IT Centre South
  • Sondogwahak-ro, Yeonsu-gu
  • Incheon, 21999
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Voronoi Stock Performance

As of 13-Nov-2026, Voronoi’s stock price is $83.18. Its current market cap is $1.53B with 18.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$83.18 $82.07 $66.04 - $253.21 $1.53B 18.4M 78.7K -$2.61

Voronoi Financials Summary

As of 30-Jun-2026, Voronoi has a trailing 12-month revenue of $2.87M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,169,176 2,690,516 931,158 651,915
Revenue 2,868 5,279
EBITDA (50,232) (33,842) (23,866) (24,998)
Net Income (47,637) (30,009) (23,902) (28,183)
Total Assets 86,661 118,912 50,007 73,450
Total Debt 21,917 27,647 672 9,541
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Voronoi Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Voronoi‘s full profile, request access.

Request a free trial

Voronoi Patents

  • 202

    Total Documents Applications and Grants

  • Total Patents Families

  • 69

    Granted

  • 65

    Pending

  • Expiring in next 12 mo

Voronoi Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026225984-A1 Salts of heteroaryl derivative compound Pending 23-Apr-2025
WO-2026095589-A1 Heteroaryl derivative compound and use thereof Pending 29-Oct-2024
WO-2026049570-A1 Heteroaryl derivative compound and use thereof Pending 30-Aug-2024
WO-2026024165-A1 Heteroaryl derivative compound and use thereof Pending 22-Jul-2024
AU-2025253668-A1 Heteroaryl derivative compound and uses thereof Pending 11-Apr-2024 C07D487/04
To view Voronoi’s complete patent history, request access »

Voronoi Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Voronoi ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

41.78 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,585

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Voronoi’s complete esg history, request access »

Voronoi FAQs

  • When was Voronoi founded?

    Voronoi was founded in 2015.

  • Where is Voronoi headquartered?

    Voronoi is headquartered in Incheon, South Korea.

  • What is the size of Voronoi?

    Voronoi has 146 total employees.

  • What industry is Voronoi in?

    Voronoi’s primary industry is Drug Discovery.

  • Is Voronoi a private or public company?

    Voronoi is a Public company.

  • What is Voronoi’s stock symbol?

    The ticker symbol for Voronoi is 310210.

  • What is the current stock price of Voronoi?

    As of 13-Nov-2026 the stock price of Voronoi is $83.18.

  • What is the current market cap of Voronoi?

    The current market capitalization of Voronoi is $1.53B.

  • What is Voronoi’s current revenue?

    The trailing twelve month revenue for Voronoi is $2.87M.

  • What is Voronoi’s annual earnings per share (EPS)?

    Voronoi’s EPS for 12 months was -$2.61.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process